Saturday, April 20, 2024 4/20/2024

A Prospective, Randomized, Multi-centered, Placebo-controlled Clinical Trial of Oral Vancomycin in Adults with Primary Sclerosing Cholangitis

Award Number: R01FD006102
ORGANIZATION: FOOD AND DRUG ADMINISTRATION
OPDIV: FDA
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

PROJECT SUMMARY Primary sclerosing cholangitis (PSC) is an idiopathic disease of the liver characterized by ongoing inflammation of the intrahepatic- and/or extrahepatic bile ducts, which can ultimately lead to cirrhosis and end-stage liver disease (ESLD). It is often associated with inflammatory bowel disease (IBD), namely ulcerative colitis (UC). PSC patients have a reduced survival compared to the general healthy population, and many PSC patients will eventually require liver transplantation (LT) due to complications such as progression to ESLD, development of cholangiocarcinoma (CCA), a primary bile duct cancer that carries a grave prognosis, recurrent acute cholangitis (a serious biliary tree infection), or extreme symptoms related to liver disease (such as fatigue and pruritus). The diagnosis of PSC is made when there is cholestasis and imaging (narrowing and dilatation) or histological (destruction and fibrosis) evidence of PSC. Currently, there is no medical therapy proven to halt the progression of the disease. The cause of PSC is unknown; however, accumulating evidence suggests a link between PSC and the intestinal microbiota (the bacteria that live in the colon). Open-label clinical trials have shown that the use of oral vancomycin (OV) in PSC patients has resulted in normalization of the serum cholestatic marker alkaline phosphatase (ALP), which has been found to be of prognostic importance in PSC. Specifically, normalization of serum ALP appears to be associated with long-term survival free of CCA, the need for LT, or liver-related death in PSC, and persistently elevated ALP over time has been shown to be associated with serious adverse events (development of CCA, liver-related death, and need for LT). Findings from the clinical reports of OV in PSC have prompted us to examine the role of OV as a potential therapeutic agent in PSC in a larger sample of PSC subjects over an extended period. We hypothesize that in PSC patients, daily treatment with OV results in normalization of serum ALP. The results of this clinical trial will help us determine if OV can be used as treatment for PSC patients. The overall goal of this phase II, randomized, placebo-controlled clinical trial is to examine the safety, tolerability and efficacy of daily dosing (over an 18-month period) with OV, using a stepped-up dosing strategy with three increasing doses, on the clinical course, and the progression of PSC, and to compare the treated patients with those on placebo. Study subjects in the OV and placebo arms will be compared with respect to their clinical and laboratory evaluations at the defined study points.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2022	MAYO CLINIC ARIZONA	13400 E SHEA BLVD	SCOTTSDALE	AZ	85259	MARICOPA	USA	Food and Drug Administration Research	000	4	8/30/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $499,996 )
2022	2022	MAYO CLINIC ARIZONA	13400 E SHEA BLVD	SCOTTSDALE	AZ	85259	MARICOPA	USA	Food and Drug Administration Research	002	4	8/29/2022	NON-COMPETING CONTINUATION	$499,996
2022	2020	MAYO CLINIC ARIZONA	13400 E SHEA BLVD	SCOTTSDALE	AZ	85259	MARICOPA	USA	Food and Drug Administration Research	001	3	1/31/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$137,261
2022	2018	ARIZONA STATE UNIVERSITY	660 S MILL AVE STE 312	TEMPE	AZ	85281	MARICOPA	USA	Food and Drug Administration Research	000	1	1/31/2022	NEW	-$137,261
														Subtotal = $499,996

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2020	ARIZONA STATE UNIVERSITY	660 S MILL AVE STE 312	TEMPE	AZ	85281	MARICOPA	USA	Food and Drug Administration Research	000	2	8/5/2021	NON-COMPETING CONTINUATION	-$499,998
2021	2020	MAYO CLINIC ARIZONA	13400 E SHEA BLVD	SCOTTSDALE	AZ	85259	MARICOPA	USA	Food and Drug Administration Research	001	3	8/24/2021	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$499,998
2021	2020	MAYO CLINIC ARIZONA	13400 E SHEA BLVD	SCOTTSDALE	AZ	85259	MARICOPA	USA	Food and Drug Administration Research	002	3	9/6/2021	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $499,998 )
2020	2020	ARIZONA STATE UNIVERSITY	660 S MILL AVE STE 312	TEMPE	AZ	85281	MARICOPA	USA	Food and Drug Administration Research	000	2	9/4/2020	NON-COMPETING CONTINUATION	$499,998
														Subtotal = $499,998

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2018	ARIZONA STATE UNIVERSITY	660 S MILL AVE STE 312	TEMPE	AZ	85281	MARICOPA	USA	Food and Drug Administration Research	000	1	8/22/2019	NEW	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $499,999 )
2018	2018	ARIZONA STATE UNIVERSITY	660 S MILL AVE STE 312	TEMPE	AZ	85281	MARICOPA	USA	Food and Drug Administration Research	000	1	9/11/2018	NEW	$499,999
														Subtotal = $499,999

Grand Total All Awards = $1,499,993

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Prospective, Randomized, Multi-centered, Placebo-controlled Clinical Trial of Oral Vancomycin in Adults with Primary Sclerosing Cholangitis

Award Number: R01FD006102

ORGANIZATION: FOOD AND DRUG ADMINISTRATION

OPDIV: FDA

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer